Hi have a feeling that J. Kelly Ganjei might be waiting in the wings to be NWBO CEO (or at least COO). Since Amplify Bio folded last year he setup a one man consulting company called Juncture Bio that is "striving to integrate people, technologies, and processes at a critical time in the evolution of advanced therapies." I think this might just be a placeholder while he waits for DCVax approval. He is 52 and has a long history of working with LP at Cognate (he was CEO); is coauthor of a number of NWBO patents; has multiple top management roles and (aside from his board membership of Inmune Bio) is presently just a one man consulting band for the first time in his career. I think he would be perfectly placed for the job!
I think sometime post approval we might be looking at:
Linda Powers - Executive Chairperson
J. Kelly Ganjei - CEO
Dr Marnix Bosch - Global COO/ President
Mike Scott - Head of Manufacturing/ CTO
George Zavszko - SVP Operations
Alton L. Boynton. - retires (81yo)/ moves into a Senior Advisor role
Dr. Samir Khleif - CSO
Dr. Samir Khleif is from the SAB, but unlike the others, Linda Liau, Jerome Galon & Dr. John F. Smyth who are career academics, Dr. Khleif has already bridged the gap between medicine, government regulation, and corporate leadership. He served as the Special Assistant to the Commissioner of the FDA, where he led the "Critical Path Initiative for Oncology." He understands exactly how to design a trial that will satisfy regulators and most interestingly, combination therapies are his specialty. He was one of the first researchers to report that some immunotherapies can "cancel each other out" if not timed correctly. This knowledge is essential for NWBO’s next phase, that is pairing DCVax with checkpoint inhibitors or cytokines. That said, he is presently tied up as CEO of Georgiamune, but of course I am just speculating here.
Market Data 
Markets 
